FDA Proposes Faster Path for Chewable OTC Drug Updates
Published Date: 6/5/2025
Notice
Summary
The FDA is making it easier for companies to switch certain OTC pills into chewable tablets, dissolving tablets, or films without extra paperwork. This helps drug makers update their products faster while keeping safety rules in check. If approved, these minor changes could save time and money for everyone involved.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Allow minor OTC dosage-form switches
If you make over‑the‑counter (OTC) monograph drugs, the FDA proposes allowing certain minor dosage form changes — from tablets or capsules to chewable tablets, orally disintegrating tablets, or films — without issuing a separate order to amend the OTC monograph or separately finding the new dosage form to be generally recognized as safe and effective (GRASE). This change applies only when the product conforms with the proposed order, the Federal Food, Drug, and Cosmetic Act, and other applicable requirements.
Speeds updates and cuts paperwork/costs
The proposed order is intended to let drug makers update certain OTC products faster and without extra paperwork, which the FDA says could save time and money for everyone involved. If finalized, manufacturers could implement eligible dosage‑form changes more quickly than under the current separate‑order process.
Dosage changes still subject to safety rules
The FDA says the minor dosage form changes are allowed only when the products conform with the proposed order, the Federal Food, Drug, and Cosmetic Act, and other applicable requirements, so safety and legal standards remain in force. That means companies cannot use this pathway unless they meet the same safety and statutory requirements described in the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-10251, Recommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs; Draft Guidance for Industry; Availability
Hey makers of over-the-counter solid pills! The FDA just dropped a draft guide to help you make small changes to your products without a headache. Follow these tips to stay on track, save time, and avoid extra costs while keeping your meds safe and sound.
Next: 2025-10253, Over-the-Counter Monograph Condition B001: Single-Unit or Unit-Dose Containers for Over-the-Counter Monograph Drugs in Orally Disintegrating Tablet and Film Dosage Forms
The FDA wants to make sure certain over-the-counter medicines that dissolve in your mouth come in single-use packages. This change helps keep doses safe and easy to use, especially for kids and busy folks. If this rule passes, drug makers will need to update their packaging soon, which might cost a bit but will make medicine safer for everyone.